HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Angeliki P Kourounakis Selected Research

Atherosclerosis

1/2023Effect of a new squalene synthase inhibitor on an ApoE-/- mouse model of atherosclerosis.
1/2019Optimizing the Pharmacological Profile of New Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives.
9/2017Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
1/2017Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis.
11/2015Antihyperlipidemic morpholine derivatives with antioxidant activity: An investigation of the aromatic substitution.
3/2014Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
11/2010Design of more potent squalene synthase inhibitors with multiple activities.
6/2008Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit.
12/2007EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit.
3/2006Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Angeliki P Kourounakis Research Topics

Disease

10Atherosclerosis
01/2023 - 03/2006
4Edema (Dropsy)
09/2022 - 06/2002
2Neurodegenerative Diseases (Neurodegenerative Disease)
01/2007 - 07/2004
2Inflammation (Inflammations)
06/2003 - 06/2002
1Hyperlipidemias (Hyperlipidemia)
11/2015
1Muscular Diseases (Myopathy)
02/2015
1Dyslipidemias (Dyslipidemia)
03/2014
1Type 2 Diabetes Mellitus (MODY)
04/2013
1Metabolic Syndrome (Dysmetabolic Syndrome X)
04/2013
1Coronary Artery Disease (Coronary Atherosclerosis)
12/2007
1Brain Ischemia (Cerebral Ischemia)
01/2007

Drug/Important Bio-Agent (IBA)

8AntioxidantsIBA
09/2022 - 01/2007
5Farnesyl-Diphosphate Farnesyltransferase (Squalene Synthase)IBA
01/2023 - 12/2007
3morpholineIBA
09/2017 - 11/2015
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2019 - 02/2015
2CholesterolIBA
06/2008 - 12/2007
2EP2302IBA
06/2008 - 03/2006
2LipidsIBA
12/2007 - 03/2006
2EP2306IBA
12/2007 - 03/2006
2Free RadicalsIBA
06/2003 - 06/2002
1Apolipoproteins E (ApoE)IBA
01/2023
1folinIBA
09/2022
1Gallic AcidIBA
09/2022
1LDL Lipoproteins (beta Lipoproteins)IBA
01/2019
1Hypolipidemic Agents (Antihyperlipidemics)IBA
01/2019
11,4-benzothiazineIBA
01/2017
1oxidized low density lipoproteinIBA
11/2015
1Hypoglycemic Agents (Hypoglycemics)IBA
04/2013
1diphenyl (biphenyl)IBA
12/2007
1Ibuprofen (Motrin)FDA LinkGeneric
01/2007
1Glutathione (Reduced Glutathione)IBA
01/2007
1Proline (L-Proline)FDA Link
01/2007
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
07/2004
1Lipoxygenase (Lipoxygenase-1)IBA
06/2003
1Indomethacin (Indometacin)FDA LinkGeneric
06/2003
1alkanninIBA
06/2002
1Hydroxyl RadicalIBA
06/2002
1shikoninIBA
06/2002
1Dimethyl Sulfoxide (DMSO)FDA LinkGeneric
06/2002